<DOC>
	<DOC>NCT00447421</DOC>
	<brief_summary>The purpose of this study is to determine the recommended dose of pemetrexed, cisplatin and radiotherapy in the treatment of patients with Small Cell Lung Cancer.</brief_summary>
	<brief_title>A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Small Cell</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Measurable disease with diagnosis of Small Cell Lung Cancer. Performance status of 0 to 1 on the Eastern Cooperative Oncology Group performance status schedule. Patients must be at least 18 years of age and have at least a 12week life expectancy. No prior chemotherapy and/or prior thoracic radiotherapy. Adequate pulmonary function and organ function. Patients with myocardial infarction within the preceding six months. Diagnosis of a serious concomitant systemic disorder. Prior radiotherapy to the lower neck or abdominal region. Significant weight loss. Concurrent administration of any other antitumor therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>